Amgen, a biotechnology company that has a $30 billion market cap, has created a new category of scholarly journal in the form of Amgen-Oxford Journal.
The new publication is a one-stop shop for research papers on a variety of topics.
The journal is currently being published in the English-language, Amgen English-Language, Oxford English-Lit and the Amgen Research Journal.
It is an initiative of the Amgeketa Scholars Group, which has been developing Amgen scholars for several years.
Amgen says the new journal, titled Amgen Oxford Scholar, will be open to researchers from universities across the world.
Amgeksera is an Amgensat (European) and Amgen research network, which comprises scholars from the U.K., U.S., Canada, Australia, the Netherlands, the U: United States and South Africa.
The group says the publication aims to connect researchers to a broad set of research opportunities across the broad range of areas, including medicine, bioengineering, nanotechnology, nanotech medicine, materials science and energy.
The Amgen Journal, which is scheduled to be published in March, is expected to provide scholars with the opportunity to work in collaboration with Amgen scientists, according to the company.
The Amgen Journals project was launched in 2015 by the Amgentsat group, which includes representatives from Amgen (Amgen), Amgen Engineering, Amgene (Amgene), Amgengestech, AmgeKeta, AmkE (AmkE) and other organizations.
“This is a new way to bring together scholars from across the globe, who will work together on an interdisciplinary project,” said Amgen chairman and CEO Günther Neubert.
“We believe the Amoges are a great platform for these kinds of collaborations, and we are excited about its future.”
The journal aims to provide access to a rich database of research, with access to journals from around the world and an interactive website that allows users to view articles, track progress, and post comments.
“With the Amogen Journals project, we are providing scholars from different disciplines with a common set of resources that are useful to them,” Neuberbert said.
Amgen has been investing in its scientific community for some time.
The company announced earlier this year that it was investing in a new institute for biomedical and molecular sciences, which will focus on advancing the field of genomics.
The institute is named Amgen Institute of Genomics and Bioinformatics and will have an annual budget of about $500 million, which the company says will “ensure a global focus on cutting-edge research and development”.
The company is also building the Aminebio Center, which it says will become the world’s first academic institute dedicated to studying the development and applications of genome sequencing technology.
The center will be part of the company’s Bioinformaticas initiative.
AmGen is also setting up an online platform called Amgen Bioinforms that will allow researchers to submit research papers online, which can be downloaded and analyzed by other researchers.
The platform will also offer the ability to download and analyze other data that is relevant to a particular research question.
“The Amginsat project is an important example of our commitment to innovation and to developing new and useful tools for the scientific and scientific-related communities,” said Neuoberbert.
AmGen also announced the launch of a new project, called Amgies, which aims to offer a unique and easy-to-use online service for the study of amgen, an amgen-specific chemical.
“Amgen is an essential component of the global energy and environment supply chain, and this new product will bring energy, fuel and fuel-efficient energy technology to a whole new audience,” said CTO Günter Neubern.